EUVIMEDEUVIMED entdecken
Crossref

Indocyanine Green-Labeled Antibodies Cotargeting CDCP1 and Mesothelin for Fluorescence-Guided Imaging of Pancreatic Cancer

Johnny X Huang iD, Biao Sun iD, William McGahan, David J Cavallucci, Thomas O'Rourke, Cheng Liu, Yaowu He iD, John D Hooper

Molecular Pharmaceutics · 2026

DOI: 10.1021/acs.molpharmaceut.5c01452 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Johnny X Huang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Mater Research Institute - The University of Queensland, Translational Research Institute, Woolloongabba, Queensland 4102, Australia. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Indocyanine Green, GPI-Linked Proteins, Antigens, CD. Die Arbeit nennt 76 Literaturangaben. Gefördert von: Mater Foundation, National Health and Medical Research Council, Tour de Cure.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancers due to late-stage diagnosis, aggressive progression, inadequate modalities for detection and monitoring, and treatment options, including surgery, that generally do not achieve durable responses. CUB domain containing protein 1 (CDCP1) and mesothelin (MSLN) are cell surface proteins, commonly expressed at elevated levels in PDAC, that are potential targets for detection and treatment of these tumors. In this study, we generated anti-CDCP1 antibody ch10D7 and anti-MSLN antibody amatuximab conjugated with the near-infrared fluorophore indocyanine green (ICG). With the goal of characterizing ch10D7 ICG and anti-MSLN ICG for detection of PDAC, we noted that ICG labeling did not impact the affinity or specificity of either antibody. Both ICG-labeled antibodies selectively accumulated in subcutaneous and orthotopic PDAC models in mice, as visualized by in vivo fluorescence imaging. Postmortem fluorescence endoscopy imaging clearly delineated tumors, with optimal signal observed at 120 h post agent administration. Demonstrating specificity in vivo, depletion of CDCP1 and MSLN abolished tumor localization in xenografts of, respectively, ch10D7 ICG and amatuximab ICG . Quantitative ex vivo fluorescence analysis of excised xenografts demonstrated that combining ch10D7 ICG and amatuximab ICG enhances tumor-associated fluorescence by 2.8- to 12.5-fold compared with either agent alone. The results support the potential of dual-targeted, antibody-based fluorescence imaging for enhanced intraoperative visualization and excision of PDAC, including for tumors with heterogeneous expression of either or both of the targeted receptors CDCP1 and MSLN.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsIndocyanine GreenGPI-Linked ProteinsAntigens, CDAntigens, NeoplasmCell Adhesion MoleculesCarcinoma, Pancreatic DuctalAnimalsMesothelinHumansMiceCell Line, TumorAntibodies, MonoclonalOptical ImagingFemaleMice, NudeFluorescent Dyes

Stichwörter der Autor:innen

CDCP1MSLNendoscopyindocyanine greenintraoperative imagingpancreatic cancer

Substanzen

MesothelinIndocyanine GreenMSLN protein, humanGPI-Linked ProteinsAntigens, CDAntigens, NeoplasmAntibodies, MonoclonalCell Adhesion MoleculesCDCP1 protein, humanamatuximab

Autor:innen und Institutionen

  • Mater Research Institute - The University of Queensland, Translational Research Institute, Woolloongabba, Queensland 4102, Australia.
  • Faculty of Medicine, The University of Queensland, Saint Lucia, Queensland 4072, Australia.
  • Department of General Surgery, Royal Brisbane and Women's Hospital, Herston, Queensland 4029, Australia.
  • Department of Hepatobiliary and Pancreatic Surgery, Princess Alexandra Hospital, Woolloongabba, Queensland 4102, Australia.
  • Department of Pathology, Princess Alexandra Hospital, Woolloongabba, Queensland 4102, Australia.
  • Envoi Specialist Pathologists, Kelvin Grove 4059, Australia.

ORCID-Profile: Johnny X Huang, Biao Sun, Yaowu He

Förderung

  • Mater Foundation
  • National Health and Medical Research Council
  • Tour de Cure
  • PanKind, The Australian Pancreatic Cancer Foundation

Zitieren

APA

Huang, J. X., Sun, B., McGahan, W., Cavallucci, D. J., O'Rourke, T., Liu, C., He, Y., & Hooper, J. D. (2026). Indocyanine Green-Labeled Antibodies Cotargeting CDCP1 and Mesothelin for Fluorescence-Guided Imaging of Pancreatic Cancer. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01452

Vancouver

Huang JX, Sun B, McGahan W, Cavallucci DJ, O'Rourke T, Liu C, et al. Indocyanine Green-Labeled Antibodies Cotargeting CDCP1 and Mesothelin for Fluorescence-Guided Imaging of Pancreatic Cancer. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.5c01452

BibTeX
@article{Huang2026,
  author = {Huang, Johnny X and Sun, Biao and McGahan, William and Cavallucci, David J and O'Rourke, Thomas and Liu, Cheng and He, Yaowu and Hooper, John D},
  title = {Indocyanine Green-Labeled Antibodies Cotargeting CDCP1 and Mesothelin for Fluorescence-Guided Imaging of Pancreatic Cancer},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  doi = {10.1021/acs.molpharmaceut.5c01452}
}
Kostenlos starten →